The Pharmacy Times® Breast Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to cancers that occur in the breast, including invasive ductal carcinoma, invasive lobular carcinoma, and less common forms of the disease.
October 22nd 2024
Multiple P13K inhibitors have showed promise in treating genetically-mutated forms of breast cancer.
Strategies to Enhance CDK4/6 Inhibitor Adherence in mBC
May 14th 2024Heather Moore, BCOP, CPP, PharmD, discusses patient adherence to CDK4/6 inhibitors in clinical practice, emphasizing the importance of educating patients on drug efficacy and potential toxicities, monitoring for adverse events, and following up with patients to ensure better adherence.
Watch
Highlighting the Available CDK4/6 Inhibitors
May 7th 2024Key opinion leaders discuss the characteristics they consider when selecting among the different CDK4/6 inhibitors for individual patients, emphasizing the importance of evaluating the toxicity profiles of medications to choose the most appropriate therapy, as well as considering sequencing biomarkers and social determinants of health.
Watch
Evaluating the Impact of Metastatic Breast Cancer on Patients
May 7th 2024An expert panel discusses the clinical and economic impact of metastatic breast cancer (mBC) on patients, the prognosis for those with mBC, the three FDA-approved CDK4/6 inhibitors for HR+/HER2- mBC, and the importance of overall survival as a clinical trial endpoint and its relevance to clinical practice.
Watch
Enhancing Breast Cancer Treatment: Expanding CDK4/6 Inhibitor Use in the Early-Stage Setting
April 15th 2024Danielle Roman, PharmD, BCOP, discusses the efficacy and safety outcomes of CDK4/6 inhibitors in early-stage breast cancer, as well as key considerations for CDK4/6 inhibitors in this indication.
Watch
Advancing Pharmacists’ Role in Personalized Treatment for Breast, Prostate, and Lung Cancer
Precision oncology represents an evolution in therapeutic practice.
Read More